National Heart Failure Registry

Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age18+
SponsorNational Medical Research Center for Cardiology, Ministry of Health of Russian Federation

About this trial

A prospective-retrospective observational registry of patients diagnosed with chronic heart failure in the regions of the Russian Federation.

The study is non-interventional and does not involve any interventions in clinical practice, the choice of treatment methods (including the type of medical device used and the method of surgical intervention) and examination.

A control observation group is not intended.

Eligibility criteria

This trial does not accept healthy volunteers

Qualifiers

Any stage and/or any class of CHF

Disqualifiers

Subjects whose source records cant be obtained for the analysis

Trial population

At least 3% of CHF subjects in the target regions of Russia will be included in that trial by performing thier medical records analysis

Trial design

Design model

Other

Time perspective

Other

Treatments tested in this trial

Not listed

Trial groups

No trial groups listed

Trial outcomes

Primary outcomes

1

Age of subjects with different phenotypes and stages of CHF

Time frame
Every 12 months, up to 3 years
2

Female to male sex ratio of subjects with different phenotypes and stages of CHF

Time frame
Every 12 months, up to 3 years
3

Clinical status of subjects with different phenotypes and stages of CHF

Time frame
Every 12 months, up to 3 years
4

Proportion of employable and working subjects with different phenotypes and stages of CHF

Time frame
Every 12 months, up to 3 years

Secondary outcomes

1

Proportions of subjects with an increase in EF ≥10% and a decrease in the functional class of CHF by 1 point

Time frame
Every 12 months, up to 3 years
2

The proportion of subjects hospitalized for decompensated CHF in the departments of therapeutic and cardiology profiles *

Time frame
Every 12 months, up to 3 years
3

Proportion of subjects with newly diagnosed type 2 diabetes*

Time frame
Every 12 months
4

Proportion of subjects with deterioration of renal function*

Time frame
Every 12 months, up to 3 years

Other outcomes

Sponsors and contacts

Click on the lead sponsor to view all of their trials.